ABUS

Arbutus Biopharma Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↑ 7/10
  • Value↓ 0/10
Arbutus Biopharma sales and earnings growth
ABUS Growth
Good
  • Revenue Y/Y↑ 116.64%
  • EPS Y/Y↑ 46.51%
  • FCF Y/Y↑ 36.95%
Arbutus Biopharma gross and profit margin trends
ABUS Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -289.40%
  • ROIC 5Y↓ -63.76%
Arbutus Biopharma net debt vs free cash flow
ABUS Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -386.9

Arbutus Biopharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗